The GIFT Nifty futures, which is an early indicator of the Nifty50 index stocks, was trading lower by 80 points at 24,746 indicating that the domestic benchmark indices are likely to make a negative start on Thursday.

Earlier on Wednesday, 18 June, Domestic benchmark indices S&P BSE Sensex slumped by 138.64  points or 0.17% and settled at 81,444.66 while the Nifty50 traded 0.17% lower or 41.35 points, closing at 24,812.05. 

Here are some stocks that are likely to remain in focus on 19 June.

Vodafone Idea: VI has partnered with AST SpaceMobile to offer direct-to-mobile satellite broadband services. This collaboration will enable users to access internet and voice services even in remote locations without relying on nearby mobile towers.

Zydus Lifesciences: Zydus Lifesciences announced that the US Food and Drug Administration (USFDA) has concluded its Good Manufacturing Practice (GMP) follow-up inspection at the company’s oncology injectable facility at SEZ-1, Ahmedabad. The inspection, conducted between 9 and 18 June, resulted in two observations, none related to data integrity.

Tata Elxsi: The company has announced signing a Memorandum of Understanding (MoU) with Infineon Technologies to co-develop EV application-ready solutions for the Indian market. This collaboration aims to accelerate the deployment of cost-effective, safety-compliant, and automotive-grade subsystems by combining Infineon’s semiconductor innovation with Tata Elxsi’s design and integration capabilities.

Hero MotoCorp: Hero MotoCorp will launch the VIDA VX2 electric scooter under a subscription-based Battery-as-a-Service (BaaS) model starting 1 July. The flexible pay-as-you-go ownership plan will allow customers to finance the scooter’s chassis and battery separately, turning large upfront costs into affordable monthly payments.

Abbott India: Abbott India entered into a strategic distribution agreement with MSD Pharmaceuticals to widen the reach of MSD’s oral anti-diabetic products in India. Under this deal, Abbott will market MSD’s leading sitagliptin-based brands, Januvia, Janumet, and Janumet XR, by using its vast distribution network, ensuring continued leadership in the category even after the expiry of exclusivity rights.

The future of investing is here!
Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!